Use este identificador para citar ou linkar para este item: http://repositorio.ufla.br/jspui/handle/1/45448
Registro completo de metadados
Campo DCValorIdioma
dc.creatorYadav, Manisha-
dc.creatorDhagat, Swasti-
dc.creatorEswari, J. Satya-
dc.date.accessioned2020-11-11T17:16:56Z-
dc.date.available2020-11-11T17:16:56Z-
dc.date.issued2020-12-
dc.identifier.citationYADAV, M.; DHAGAT, S.; ESWARI, J. S. Emerging strategies on in silico drug development against COVID-19: challenges and opportunities. European Journal of Pharmaceutical Sciences, [S.l.], v. 155, Dec. 2020.pt_BR
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0928098720303109pt_BR
dc.identifier.urihttp://repositorio.ufla.br/jspui/handle/1/45448-
dc.description.abstractThe importance of coronaviruses as human pathogen has been highlighted by the recent outbreak of SARS-CoV-2 leading to the search of suitable drugs to overcome respiratory infections caused by the virus. Due to the lack of specific drugs against coronavirus, the existing antiviral and antimalarial drugs are currently being administered to the patients infected with SARS-CoV-2. The scientists are also considering repurposing of some of the existing drugs as a suitable option in search of effective drugs against coronavirus till the establishment of a potent drug and/or vaccine. Computer-aided drug discovery provides a promising attempt to enable scientists to develop new and target specific drugs to combat any disease. The discovery of novel targets for COVID-19 using computer-aided drug discovery tools requires knowledge of the structure of coronavirus and various target proteins present in the virus. Targeting viral proteins will make the drug specific against the virus, thereby, increasing the chances of viral mortality. Hence, this review provides the structure of SARS-CoV-2 virus along with the important viral components involved in causing infection. It also focuses on the role of various target proteins in disease, the mechanism by which currently administered drugs act against the virus and the repurposing of few drugs. The gap arising from the absence of specific drugs is addressed by proposing potential antiviral drug targets which might provide insights into structure-based drug development against SARS-CoV-2.pt_BR
dc.languageen_USpt_BR
dc.publisherElsevierpt_BR
dc.rightsrestrictAccesspt_BR
dc.sourceEuropean Journal of Pharmaceutical Sciencespt_BR
dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)pt_BR
dc.subjectCoronaviruspt_BR
dc.subjectTarget proteinspt_BR
dc.subjectDrug repurposingpt_BR
dc.subjectComputational drug discoverypt_BR
dc.titleEmerging strategies on in silico drug development against COVID-19: challenges and opportunitiespt_BR
dc.typeArtigopt_BR
Aparece nas coleções:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Arquivos associados a este item:
Não existem arquivos associados a este item.


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.